English
Polski
Español
українська
Osteoporosis treatment and the risk of fractures
Why should we treat osteoporosis?
2016-10-13
Is there a risk that repetitive sports-related injuries accelerate the progression of spondyloarthritis?
Should we perform ultrasound in patients with polymyalgia rheumatica?
Does anti-tumor necrosis factor therapy inhibit the progression of radiological changes in the spine?
In 2015, the ACR and the EULAR published new guidelines on the management of PMR. What do they change in clinical practice?
What are the emerging treatment modalities for osteoporosis?
In 2012, the ACR and the EULAR have defined new classification criteria for PMR. Are these criteria effective in clinical practice? What have been the major changes introduced in the last update?
Bearing in mind the availability of more personalized treatments nowadays, are there some subgroups of patients with osteoporosis that would specifically benefit from certain drugs?
Could you comment on the new drugs used in spondyloarthritis?
Are steroids still the mainstay treatment for giant cell arteritis? Are there perspectives for new therapies with fewer adverse effects?
